Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dabigatran etexilate 75 mg hard capsules

Active Ingredient:
dabigatran etexilate
Company:  
Laboratorios Liconsa, S.A. See contact details
ATC code: 
B01AE07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Alert Card

Information about the potential risk of bleeding during treatment with dabigatran etexilate and guidance on how to manage that risk.

{pdf_link}

Prescriber Guide for paediatric use

{healthcare_pro_orange} For Healthcare Professionals
{pdf_link}

Prescriber Guide for venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

{healthcare_pro_orange} For Healthcare Professionals

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Laboratorios Liconsa, S.A.
Company image
Address
Street Manuel Pombo Angulo, 28 3rd floor, Madrid, 28050, Spain
Medical Information e-mail
[email protected]
Medical Information Direct Line
+34 619 27 55 90
Telephone
+34 619 27 55 90
Fax
+34 949 26 42 58
Customer Care direct line
+34 91 771 15 00
WWW
https://www.chemopharmaceuticals.com/
WWW
https://www.insudpharma.com/